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In the last decades, nanosized carrier 
systems for pharmaceutically active com-
pounds have not only attracted the atten-
tion of researchers worldwide, but also 
emerged into clinical trials or even became 
approved drugs.[1–3] Many attempts have 
been made to modify the biodistribution 
toward higher target site accumulation, 
which requires engineering nanoparticle 
properties, e.g., size and surface.[4] In this 
context, the potential formation of a pro-
tein corona around nanoparticles is of pri-
mary interest, since this process changes 
the nanoparticle surface properties and 
thus co-determines the biological profile 
in the body.[5–7]
Protein corona formation of various nan-
oparticles and its impact on pharmacoki-
netics has been carefully studied.[8–10] The 
tested nanoparticles were mainly inorganic 
or organic colloidal nanoparticles,[11–14] for 
which a pronounced corona formation was 
observed upon contact with plasma proteins. 
This protein corona modifies the interaction 
The current understanding of nanoparticle–protein interactions indicates 
that they rapidly adsorb proteins upon introduction into a living organism. 
The formed protein corona determines thereafter identity and fate of nano-
particles in the body. The present study evaluates the protein affinity of 
three core-crosslinked polymeric nanoparticles with long circulation times, 
differing in the hydrophilic polymer material forming the particle surface, 
namely poly(N-2-hydroxypropylmethacrylamide) (pHPMA), polysarcosine 
(pSar), and poly(ethylene glycol) (PEG). This includes the nanotherapeutic 
CPC634, which is currently in clinical phase II evaluation. To investigate 
possible protein corona formation, the nanoparticles are incubated in 
human blood plasma and separated by asymmetrical flow field-flow frac-
tionation (AF4). Notably, light scattering shows no detectable differences in 
particle size or polydispersity upon incubation with plasma for all nanoparti-
cles, while in gel electrophoresis, minor amounts of proteins can be detected 
in the particle fraction. Label-free quantitative proteomics is additionally 
applied to analyze and quantify the composition of the proteins. It proves 
that some proteins are enriched, but their concentration is significantly 
less than one protein per particle. Thus, most of the nanoparticles are not 
associated with any proteins. Therefore, this work underlines that polymeric 
nanoparticles can be synthesized, for which a protein corona formation does 
not take place.
The ORCID identification number(s) for the author(s) of this article 
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with cells,[10] can shield recognition units,[15] but its role for biodis-
tribution and circulation is still far from well understood.[8,16]
Except for liposomes, other types of nano-sized drug delivery 
systems, such as polymeric micelles or more complex polymer 
constructs like cylindrical polymer brushes[17] have been so far 
hardly investigated with respect to protein corona formation (for 
comparison between the structures of these nanoparticles and 
the colloidal nanoparticles discussed above, see Figures S1 and 
S2 in the Supporting Information).[8,18–20] However, the former 
are interesting, since polymeric micelles are in advanced stages 
of clinical testing (e.g., CPC634 (phase II)[21] and NC-6004 Nan-
oplatin (phase III)[22]).
To evaluate the formation of a protein corona, separation of 
the nanoparticle–protein-complex from unbound proteins used 
for incubation or upon in vivo exposure becomes a necessity. 
The isolation of incubated nanoparticles (colloids and inorganic 
nanoparticles) from unbound proteins was mainly performed 
by centrifugation, which is a separation method based on dif-
ferences in density.[23] Thus, this method allows only the puri-
fication of nanoparticles with a higher density but can hardly 
be used for low density particles, such as polymeric micelles 
and polymer brushes.[24] Only recently, size exclusion tech-
niques such as size exclusion chromatography and asymmet-
rical flow field-flow fractionation (AF4) have been employed 
for this purpose.[19,25,26] AF4 is a separation technique, which 
can be applied for the separation of particle and protein mix-
tures in the size range between 1  nm and 1  µm.[27,28] It con-
sists of a separation channel with a flow gradient in which 
the particles are separated by an additional vertical force field 
depending on their diffusion coefficient.[29,30] During an AF4 
measurement, the injected particles are pushed by the vertical 
cross flow toward the membrane at the bottom of the channel. 
Due to Brownian motion, the particles are diffusing back into 
the middle of the channel. Since smaller particles are faster 
than larger ones (because of their higher diffusion coefficient), 
they are concentrating faster in the middle, thus eluting first 
through the channel outlet. In contrast to conventional size 
exclusion chromatography, in AF4 the contact to the interface 
and the shear forces are substantially reduced, which leads to 
very mild separation conditions, minimizing perturbations of a 
potential protein corona.[26,31] Based on this method, Landfester 
and coworkers recently fully characterized the protein corona of 
Lutensol AT50-coated polystyrene nanoparticles and PEG func-
tionalized liposomes, identifying all adsorbed proteins.[19,26]
Here, we present a purification procedure based on AF4 for 
the separation of smaller polymeric architectures (Rh: 20–30 nm) 
that are hardly separable by centrifugation. We isolated poly-
meric nanoparticles from unbound blood plasma components 
and characterized them by dynamic light scattering, gel electro-
phoresis and mass spectrometry, with the goal of studying their 
protein corona and their affinity to specific plasma proteins. 
As model systems we selected polymer micelles and a mole-
cular polymer brush, which are close to established nanocar-
riers concerning their hydrophilic shell (see Figure 1). As shell 
material we chose either i) poly(ethylene glycol) (PEG),[25,32]  
ii) poly(N-2-hydroxypropylmethacrylamide) (pHPMA)[18,33,34] or 
iii) polysarcosine (pSar),[35,36] as they are not only considered pro-
tein resistant but furthermore are part of drugs in preclinical 
or clinical investigations.[21,37–39] Moreover, all these polymers 
are hydrophilic and do not possess a net charge to reduce 
adsorption of proteins by electrostatic and hydrophobic inter-
actions.[40,41] In addition, it was recently demonstrated that the 
pSar based nanoparticles maintain their diffusion coefficient 
and thus hydrodynamic radius even in full human blood.[42] 
From the chemical side PEG and pSar follow the Whitesides 
Rules for protein resistant materials, as they are hydrophilic and 
only weak H-bond acceptors without a net charge and H-bond 
donor properties.[43] Moreover, pSar and PEG possess iden-
tical solution properties in aqueous solution.[44] pHPMA, how-
ever, possesses H-bond donor-properties (amide and hydroxyl 
proton). Nevertheless, pHPMA homopolymers of 65  kDa dis-
play a blood half-life of 10 h.[45] Generally, surface coatings with 
these polymers reduce protein adsorption.[43,46] In this context, 
the interactions between PEG and pSar were investigated using 
molecular dynamic simulations, where only minimal protein 
interactions were found.[47]
Here we want to use the AF4 technique, for a comparative 
analysis of three micellar carrier systems to determine their 
protein corona.
2. Results and Discussion
For this study we selected three polymer-based nanoparti-
cles (see Figure 1), which have a surface either based on PEG, 
pSar or pHPMA. Physicochemically, all selected nanoparticles 
resemble core-crosslinked polymeric micelles although they 
were synthesized in rather different ways (see Figure S1 in the 
Supporting Information). These are two polymer micelles based 
on amphiphilic block copolymers with poly(N-2-hydroxypropyl-
methacrylamide) (pHPMA-NP)[48] or poly(ethylene glycol) (PEG-
NP)[32] as the hydrophilic block and they are crosslinked in the 
hydrophobic block after self-assembly (see Figure S1 in the Sup-
porting Information). The third system is a polymer brush with 
a hydrophobic N-acylated poly(lysine) main chain and a hydro-
philic poly(sarcosine) shell (pSar-NP) (Figure S1, Supporting 
Information).[49] These three nanoparticles were synthesized 
according to the published protocols.[32,48,49] It is important to 
state that the presented nanoparticles differ in chemistry, but 
share a common feature, which is the covalent stabilization of 
the core to assure stability after injection into a living species.[17] 
In fact, all systems represent single large molecules, in case of 
PEG- and pHPMA-NPs with a core shell structure, in which the 
exchange dynamics between micelles and unimers are abol-
ished. Consequently, all three systems can be regarded as stable 
nanoparticles with a dense, hydrophilic polymer shell even in 
contact with plasma proteins or cell membranes.
All nanoparticles were characterized by multiangle laser light 
scattering in aqueous solution ensuring that the particles are of 
comparable size. They are in a size range of Rh = 20–30 nm and 
display a polydispersity (μ2) of below 0.11, indicating nanoparti-
cles with narrow size distribution. In addition, all three systems 
reveal a ζ-potential between −7 and −0.1 mV, which is considered 
as neutral charge for nanoparticles.[50] Data on size distribution 
and ζ-potential of the individual particles are shown in Figure 1 
and Figures S3–S5 in the Supporting Information. Thus, these 
nanoparticles fulfill the preconditions for a good in vivo circula-
tion,[40] which was verified in Figure 1a–d.
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Figure 1. Overview of the hydrophilic shell materials of the characterized nanoparticles. Chemical structure of the utilized polymers, polymerization 
type, hydrodynamic diameter, polydispersity (µ2) and zeta potential are shown. Circulation times of the three tested nanoparticles. a) Blood circulation 
time of the PEG-NPs in mice (n = 3). b) Blood circulation time of pSar-NPs in mice (n = 5). c) Blood circulation time of p(HPMA)-NPs in mice (n = 5). 
d) Blood circulation time of PEG-NPs in patient with progressive solid tumors (n = 5). Note, that the first measurement point for PEG NPs in mice 
and patient was 5 min post i.v. injection, for the p(Sar) NPs 5 min post i.v. injection, for p(HPMA) NPs 15 min post i.v. injection. 100% of docetaxel 
concentration and fluorescence intensity correspond to the concentration/intensity at the earliest time point.
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For pSar (n = 5) and pHPMA NPs (n = 5) the pharmacoki-
netic profile was determined in Balb/c white mice (in case of 
pHPMA-NPs Balb/c mice bearing 4T1 tumors). For this pur-
pose, both nanoparticles were labelled with a near-infrared dye 
via copper-free click chemistry (see experimental part). The 
experiments ex vivo (blood samples from in vivo experiments) 
revealed a prolonged blood circulation profile of both pSar and 
pHPMA NPs with blood half-lives above 24 h (see Figure 1b,c).
In the case of the PEG NPs, the blood half-life was deter-
mined by measuring total docetaxel (i.e., sum of already 
released and still bound) in the blood of mice (n = 3) and men 
(n = 5) with progressive solid tumors.[21,51] It is thus not one-to-
one comparable to the labeled pSar and pHPMA NPs. Thereby 
it was found that—in mice—a single intravenous injection ena-
bled complete regression of both small and established tumors. 
The systemic circulation of PEG NPs (CPC634) was obtained in 
a dose escalation phase 1 study.[52] The experiments revealed a 
blood half-life of 7.4 h in mice, but interestingly 31.6 h in men 
(see Figure  1a,d). These results indicate that the three nano-
particles investigated in this study circulate very well in vivo 
in mice. Prolonged circulation times are of major importance, 
since they enhance the chance for passive or active targeting 
and thus for accumulation in the tumor tissue. This could be 
verified for similar or identical structures of the tested nano-
particles (see section “Tumor accumulation of studied nanopar-
ticles” in the Supporting Information). In addition and more 
important, the PEG NPs (CPC634) show excellent pharmacoki-
netics in patients.[52] Hereafter, we considered a comparative 
study of the interaction of the three nanoparticles with plasma 
proteins important to gain a better understanding of the role of 
protein affinity and protein corona formation on the circulation 
times.
To determine interactions with plasma proteins, the three 
nanoparticles were incubated in EDTA-stabilized, full human 
plasma (pooled from six healthy donors) for 1 h at 37 °C and 
continuously agitated (500  rpm) to simulate the conditions in 
the body, where diffusion of cells and proteins constantly occur 
in the blood flow. As previously shown, one hour of incubation 
is sufficient for protein corona formation.[53,54]
Since the separation of nanoparticles and plasma compo-
nents by centrifugation is hardly possible for systems with den-
sities comparable to plasma, such as polymeric micelles, we 
have chosen to apply asymmetrical flow field-flow fractionation 
for the separation of nanoparticles and plasma components. 
Here, we specifically optimized AF4 separation conditions for 
each nanoparticle allowing the exclusive elution of the incu-
bated nanoparticles and their separation from the plasma 
proteins. The isolated nanoparticle–protein-complex was then 
measured by dynamic light scattering to characterize any size 
increase due to protein adsorption. Moreover, protein affinity 
was investigated qualitatively and quantitatively by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and label-free liquid chromatography-high-resolution mass 
spectrometry (LC-MS). A schematic illustration of the separa-
tion procedure is displayed in Figure 2.
Since most single proteins in blood plasma are in the size 
range of 6–10 nm,[55] thus smaller than the investigated nano-
particles, they are eluting prior to the nanoparticles in the AF4 
channel (Figure 2).[19,26]
The AF4 elugrams for the three polymeric nanoparticles 
are shown in Figure  3a–c. A run of pure plasma is pictured 
in red resulting in an intense peak between 6.5 and 10  min 
at the beginning of the measurements, which consists of the 
main fraction of small proteins (larger objects like lipoproteins 
and particles aggregates appear—at the end of each measure-
ment—in the rinse peak). The elugrams of nanoparticles, 
which were incubated with phosphate buffered saline (PBS) 
instead of plasma, are presented in green. Since the nanopar-
ticles are larger than most of the proteins they are eluting later 
and depending on the crossflow at different retention times 
(see experimental part). The elugrams of the mixtures between 
nanoparticles and pure plasma after incubation are shown in 
blue. During the measurements we observed—for all three 
cases—no sign of any significant loss of particles or proteins 
by unspecific adsorption in the device (loss of UV-intensity 
or adsorption onto the membrane, see Figure S6 in the Sup-
porting Information experiments to plasma loss) or aggrega-
tion in the AF4 channel. Furthermore, the nanoparticle peaks 
did not undergo any shift to later retention times after incu-
bation (UV and MALS detector, for MALS detector see Figure 
S7 in the Supporting Information), which is a first indication 
that the size of the particles is not significantly altered during 
incubation with plasma. Nanoparticles, which aggregate with 
proteins and thus increase in size, would elute at later reten-
tion times or even during the rinsing due to the smaller dif-
fusion coefficient of the aggregate (see examples for PS NPs 
and different micelles in Figure S8 in the Supporting Informa-
tion). This fact was confirmed by multiangle-light scattering of 
isolated particles, which were incubated with plasma or PBS 
before purification by AF4 (Figure 3d–f). For all three nanopar-
ticles the hydrodynamic radius remains the same, whether they 
were incubated in PBS or plasma. These results confirm our 
starting hypothesis that the chosen materials remain intact and 
are not subjected to any dynamics after exposure to plasma. 
Moreover, these results further indicate that there is no major 
adsorption of proteins on the nanoparticles leading to a signifi-
cant size increase of the complexes, which is in accordance to 
findings on liposomes as determined by AF4.[19] On the other 
hand, a previous study with solid nanoparticles demonstrated 
corona formation induced changes in particle size as detected 
by dynamic light scattering (DLS) or retention time shifts in 
AF4.[26] This is in agreement with a recent study from Couffin 
and coworkers, which proved that with AF4 it is possible to 
detect small size differences (5–10  nm) between different 
nanoparticles.[56]
Since we did not observe any change of the hydrodynamic 
radii of the nanoparticles from possible adsorbed proteins, we 
conducted further experiments to identify potential corona pro-
teins by SDS PAGE. Figure 4a shows a silver stained gel of the 
isolated fractions of the three nanoparticles, which were incu-
bated in plasma and purified by AF4. For all three systems a 
distinct band between 50 and 60  kDa (Figure  4a, slot 4–6) 
is visible. As the same band is the most intensive one in 1% 
plasma in slot 1 of the gel, the detected protein could be identi-
fied as human serum albumin (HSA). Since HSA is the most 
abundant protein in human blood plasma,[57] traces of it are 
probably bleeding into other fractions. With this conclusion 
it is necessary to compare the matching fraction of a control 
Small 2020, 16, 1907574
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AF4 run with pure plasma (without nanoparticles). Figure  4a 
shows this fraction for the three nanoparticles in slot 8–10, 
respectively. Both in the fraction of the control plasma run and 
the run using nanoparticles incubated with plasma there is an 
albumin band visible, indicating that HSA, as the most abun-
dant protein, is in fact co-eluting with the nanoparticles. Nev-
ertheless, the amount of albumin is still very low, since it could 
only be detected with the very sensitive silver staining, which 
has a detection limit in the sub-nanogram range.[58] (Coomassie 
stained gels did not reveal any bands on both fractions for each 
system (Figure S9, Supporting Information)).
To quantify the total amount of HSA (coeluting or adsorbed) 
in the purified nanoparticle fraction, we performed two sets of 
experiments. First, we compared the nanoparticle fraction with 
molecular polymer brushes, which had been chemically func-
tionalized with an average of 2 or 10 antibodies, by SDS-PAGE 
(see Figure S10 in the Supporting Information). These experi-
ments indicate that the total amount of coeluting or adsorbed 
proteins on the purified brushes (after AF4) is smaller than 2 
antibodies per brush. To further characterize the proteins in the 
nanoparticle fraction, we performed a comparative SDS-PAGE-
based analysis of AF4 separated fractions with various amounts 
of free, pure HSA (Figure  4b). The amount of HSA in the 
fraction of the purified brushes was determined to be 5–10 ng 
per 730 ng of brushes, i.e., on average less than one molecule 
HSA per brush. For the other types of nanoparticles, a com-
parably low amount of HSA was only detected (calculations in 
the Supporting Information). Thus, even if all HSA would be 
stably attached to the different nanoparticles, this can hardly be 
regarded as a bona fide protein corona, as less than 1 molecule 
of albumin per particle would lead to a neglectable surface cov-
erage of the nanoparticles.
Our SDS-PAGE analyses indicated that besides albumin 
there are also various other proteins detectable in the frac-
tion of the purified nanoparticles in trace amounts (less than 
albumin). Notably, most of them could also be found in the 
control plasma run, which indicates that these proteins are—at 
least to some extent—coeluting during AF4 (see Figure 4a).
We hypothesized that “true corona components” should be 
significantly enriched in AF4 runs of plasma-incubated nano-
particles relative to control fractions from pure plasma and 
pure particle runs. Therefore, to identify potential corona pro-
teins, we performed a label-free quantitative proteomic analysis 
to quantify the relative protein amounts within the AF4 frac-
tions, comparing the incubated particle containing fractions 
and the respective control fractions from plasma runs (without 
Small 2020, 16, 1907574
Figure 2. Separation procedure of nanoparticles and proteins via AF4 and analysis of the isolated nanoparticle–protein-complex. In a first step, the 
nanoparticles were incubated in full human blood plasma for 1 h at 37 °C. After the incubation, the particles were separated via asymmetrical flow field-
flow fractionation (AF4) from unbound proteins and isolated for further analysis. The size of the NP-protein-complex was characterized with multi-angle 
light scattering for detection of possible size increase due to protein adsorption. SDS PAGE and label-free quantitative proteomic analysis revealed the 
composition and amount of enriched proteins on the nanoparticles.
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NPs). For this purpose, we applied our recently described SP3-
based protocol to obtain maximal sensitivity of the quantitative 
proteomic analysis.[59]
In the AF4 fractions obtained after particle incubations 
with plasma, we quantified 126 proteins for p(Sar)-NPs, 146 
for p(HPMA)-NPS, and 128 proteins for PEG-NPs (excluding 
trypsin and human keratins). Our analyses confirmed that HSA 
constituted the major component of the proteins detected in 
the AF4 fractions of all particles (29.6–40.6% of detected poten-
tial corona components) (Figure S11, Supporting Information). 
However, it was not significantly enriched compared to the 
respective elution ranges (plasma without particles) in AF4.
This strongly indicated that a simple detection approach 
(as often used in corona analysis) may result in false posi-
tive assignments of corona proteins, as our analyses indicate 
most proteins detected by the proteomic analysis of the AF4 
fractions are in fact plasma proteins that simply co-elute with 
the NPs during AF4 or are previously bound to the particle. 
Without the analyses of the respective negative controls, and 
subsequent comparative analysis between plasma incubation 
fractions and the respective elution range of plasma without 
particles or of particles without plasma, these proteins would 
likely have been erroneously assigned as constituents of the 
protein corona.
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Figure 3. a–c) AF4 elugrams of characterized NPs (green), plasma (red), and in plasma incubated NPs (blue): a) for PEG-NPs; b) for p(Sar) NPs; c) for 
p(HPMA)-NPs. d–f) Apparent diffusion coefficient versus scattering vector of in PBS (green) and in plasma (blue) incubated NPs after isolation with 
AF4: d) for PEG-NPs; e) for p(Sar)-NPs; f) for p(HPMA)-NPs. AF4 elugrams for all three nanoparticles are showing that there is no major size increase 
or aggregation formation due to nanoparticle–protein-interactions. For all three NPs the hydrodynamic radii did not increase due to possible protein 
adsorption. Also, the diffusion coefficient is identical at seven different scattering angles (30°, 50°, 70°, 90°, 110°, 130°, 150°) indicating a narrow size 
distribution of all three nanoparticles.
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Figure 4. a) Silver stained gel of isolated fractions of p(HPMA)-, PEG-, and p(Sar)-brushes after AF4 purification. 1) Human blood plasma 1%, 2) Novex 
Sharp Pre-Stained Protein Standard, 3) Empty, 4) p(HPMA)-NP + plasma, 5) PEG-NP + plasma, 6) p(Sar)-brush + plasma, 7) Empty, 8) Plasma and PBS 
in elution area of p(HPMA)-NP, 9) Plasma and PBS in elution area of PEG-NP, 10) Plasma and PBS in elution area of p(Sar)-brush; b) Silver stained gel 
of isolated p(Sar)-brushes after AF4 purification and Human Serum Albumin at different concentrations. 1) Human blood plasma 1%, 2) Novex Sharp 
Pre-Stained Protein Standard, 3) Empty, 4) HSA 1000 ng, 5) HSA 100 ng, 6) HSA 10 ng, 7) HSA 5 ng, 8) HSA 1 ng, 9) Empty, 10) Brush and plasma after 
AF4; c) Venn-Diagrams for enriched proteins on NPs. The overlap area shows the number of proteins significantly enriched in the sample compared 
to both control conditions. d) number of enriched proteins for all particles and conditions. e) Each bar represents the complete amount of protein 
detected in the sample shown as average across all biological and technical replicates. Red reflects the percentage share of HSA, grey all other proteins 
and orange shows the partition of the significantly enriched proteins (i.e., the protein corona).
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In our experimental setting, a protein that shows enrichment 
only in the particle control condition (plasma incubated parti-
cles compared to pure particle run) is most likely co-eluting, 
since all contaminants (proteins bound to the particle before) 
are not upregulated.
A protein that shows upregulation only in the plasma control 
condition (plasma incubated particles compared to pure plasma 
run) is regarded as a potential contaminant, because in this 
condition co-eluting proteins are not upregulated.
Consequently, we consider only those proteins that are signif-
icantly enriched in both conditions at a time as parts of a poten-
tial protein corona (see also section “Explanation Protein Corona 
Analysis” in the Supporting Information). These conditions are 
met for only five proteins for the PEG-NPs. 19 proteins were 
enriched in both conditions on p(HPMA)-NPs and 30 proteins 
on p(Sar)-NPs (Figure 4c,d; Table S1, Supporting Information).
Of the 30 protein entries identified as enriched in both con-
ditions on p(Sar)-NPs, 17 are variants of Immunoglobulins 
subdomains (representing less than 17 full proteins) and 5 of 
them are keratins (likely derived from sample handling, there-
fore not relevant) which means that only 8 proteins (APOD, 
CXCL7, LG3BP, CD5L, S10A8, HRG, ANXA2 and CO3) that 
do not belong to these protein classes are potentially enriched 
on the particle. The same holds true for p(HPMA)-NPs, where 
5 immunoglobulin entries and two keratins were significantly 
enriched, resulting in only 12 proteins (HPTR, KI21B, SAMP, 
ENOA, TGM3, IC1, ITIH4, HSPB1, SAA4, APOH, CLUS and 
KPRP) potentially bound to the particle surface. In addition to 
three Immunoglobulin entries, only two proteins (ANXA2 and 
HORN) were identified as enriched on PEG-NPs. Enriched pro-
teins are listed in Tables S2–S4 in the Supporting Information.
As this seemed to indicate a protein corona formation for all 
particle systems, we next investigated the absolute amounts of 
proteins significantly enriched on the respective particles rela-
tive to the total amount detected in the AF4 fractions. Here, we 
determined the average ppm value for each protein across all 
technical and biological replicates (except of contaminants) and 
calculated their contribution to the total protein abundance.
While albumin (not significantly enriched) constituted 
30–40% of total protein, the relative percentage of the signifi-
cantly enriched proteins on the particles contributed little to 
the total amount of protein identified in the AF4 fractions for 
the three systems investigated. Our analyses revealed that the 
significantly enriched proteins represent 20.58%, 1.32%, and 
0.53% of the total amount of protein on the p(Sar)-, p(HPMA)-, 
and PEG-NPs, respectively (Figure  4e). Since we calculated 
the amount of HSA to be less than one molecule per particle, 
the amounts of significantly enriched proteins therefore have 
to be much less, also for the pSar-NPs, for which the amount 
of enriched proteins is with 20.58% (of less than one) the 
highest. An amount of 20% of maximum one protein per nano-
particle would be 2 proteins for 10 nanoparticles. These find-
ings mean that on average 80% of the nanoparticles are not 
associated with a single protein. Consequently, our analyses 
show that the large majority of nanocarrier systems used in 
this study do simply not possess a protein corona. This result 
opens the question why only a few percent of the NPs interact 
with proteins and whether this is an intrinsic property of the 
nanoparticles or more a result of some special arrangement of 
constituents in some nanoparticles (e.g., unreacted crosslink-
able groups or remaining primary amines (positively charged 
under physiological conditions)) that are the basis for the 
detected, selectively enriched proteins. We need to state clearly 
that further research is required to fully understand the under-
lying principles on a molecular level.
Taken together our results from proteomic analysis indicate 
that all three NPs show a neglectable formation of a stable protein 
corona, which is in perfect agreement with the performed DLS 
and SDS-PAGE measurements. This low amount of enriched 
proteins validates the absence of—what is usually termed as—a 
hard protein corona on these NPs. For pSar-NPs this is also in 
line with the FCS study in full blood by Negwer et al.[42]
Concerning the boundary conditions: these results apply 
after an in vitro incubation of one hour and during a separa-
tion protocol, which allows the diffusion of proteins away from 
the nanoparticle during their flow in PBS buffer. Thus, the 
AF4 experiment cannot exclude a very weak protein affinity 
(very soft corona with reversible binding), whereby (primarily) 
enriched proteins could diffuse away during separation by AF4. 
In this context it is, however, important to mention that there 
are good indications that AF4 is capable to isolate the nanopar-
ticles including the soft corona.[26] Also, an in vivo incubation of 
these nanoparticles in the body could possibly lead to a larger 
amount of enriched proteins as reported by Dawson, Kostarelos 
and coworkers for liposomal nanoparticles recollected from the 
blood of animals[25] and patients.[60]
The difference in corona formation compared to colloidal 
nanocarriers is probably a consequence of the chemical structure 
of the core crosslinked micellar architectures studied here (see 
Figures S1 and S2 in the Supporting Information). All studied 
polymeric nanocarriers provide a dense hydrophilic corona (for 
a rough estimation of the grafting density see the Supporting 
Information), which is covalently stabilized by core-crosslinking. 
Therefore, the studied nanoparticles are of a stable nature in 
plasma and do not face rearrangements of their internal struc-
ture (see ref. [17] and section “Comparison between nanoparti-
cles with a hard interface and polymeric micellar structures” in 
the Supporting Information for discussion). Thus, it is, e.g., not 
possible that shielding domains may rearrange spontaneously 
and expose hydrophobic patches, where plasma proteins can 
adsorb and build up a protein corona irreversibly.
Thus, obviously, nanoparticles are not all alike and interact 
differently with plasma proteins, whereby the variability extends 
from only some nanoparticles interacting with a protein to 
the formation of an extensive protein corona on each particle. 
This also is in agreement with results obtained previously for 
other systems like nanoparticles coated with zwitterionic struc-
tures[61,62] and self-assembled systems such as some liposomes, 
where the detected amount of proteins was also small and 
much lower than for polystyrene and silica colloids.[19] In the 
case of a zwitterionic coating the strong electrostatic binding 
of water is claimed to be responsible for the small protein 
affinity. Concerning the mentioned liposomes, it seems intui-
tive that such materials, which are relatively similar to natural 
structures, would in general also reduce interaction with pro-
teins. And—in fact—the reduced amount of proteins on these 
liposomes led to a situation, where the subsequent biological 
response was only determined by the functional groups on the 
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surface.[19] This is beneficial for active targeting and might be 
beneficial for clinical applications, as potential negative effects 
of the protein corona are unlikely to impede the pharmacoki-
netic parameters of these NPs.
In addition, our data underline the importance of appro-
priate negative controls and background subtraction when 
applying AF4 (or other size-exclusion-techniques) in combina-
tion with the highly sensitive mass spectrometric workflows for 
protein corona analysis to avoid misleading conclusions.
3. Conclusion
Our results demonstrate that only a neglectable amount of 
plasma proteins is found on polymeric nanocarriers with dense 
surface coatings of PEG, pSar or pHPMA. None of the nano-
particles increased in size after incubation and isolation from 
human plasma, while only non-significant signs of proteins 
could be detected applying SDS-PAGE with the very sensi-
tive silver staining (subnanogram detection). Interestingly, the 
amount of plasma proteins is found to be significantly less 
than one equivalent human serum albumin protein (66  kDa) 
per nanocarrier for all the three evaluated systems. Thus, most 
of the nanocarriers are not associated with any protein at all. 
This is clearly much less protein adsorption than previously 
observed for other colloidal nanoparticles[10,26,63] and it does by 
no means correspond to a dense protein corona as it is often 
discussed for nanoparticles. Therefore, intensive corona for-
mation is not a general property of nanoparticles, which is in 
accordance with recent findings for nanoparticles coated with 
zwitterionic structures[61,62] and some liposomes.[19]
It is, however, noteworthy that even under these conditions 
it is possible to identify the enriched proteins in the fractions 
of the studied polymeric nanocarriers by applying label-free 
quantitative proteomic analysis with mass spectrometry. Never-
theless, the presented methodology requires negative controls 
and carefully conducted background subtraction techniques to 
avoid misleading conclusions.
Since all nanocarriers provide significantly high plasma cir-
culation times, our results clearly demonstrate that this is a 
property of the carrier system itself and cannot be explained 
by protein corona formation. These findings may explain the 
neglectable patient variability of PEGylated polymeric nanocar-
riers in clinical phase II (CPC634),[21,52] and underline the poten-
tial of PEG, pSar and pHPMA-based carriers in nanomedicine.
4. Experimental Section
Materials: A 20-fold stock solution of the used phosphate buffered 
saline was prepared out of sodium chloride, potassium chloride, 
disodium phosphate and potassium phosphate with a final salt 
concentration of 151.7  mmol L−1. The stock solution was also filtrated 
(Millipore GHP 0.2 µm) before using it in the AF4 system.
Human blood plasma was provided from the Transfusionszentrale of 
the Medical Department of the Johannes Gutenberg-University Mainz. It 
was pooled of six healthy donors and stabilized with EDTA.
Synthesis of pHPMA-NP: Analogous to the protocol of Kramer 
et  al.,[48] core-crosslinked p(HPMA) micelles were prepared out of 
amphiphilic poly(N-(2-hydroxypropyl) methacrylamide)-b-poly(lauryl 
methacrylate-ran-hymecromone methacrylate) block copolymers by 
solvent switching. After obtaining the micelles the hymecromone units 
in the hydrophobic block were dimerized in a [2 + 2] photocycloaddition 
by UV light irradiation to provide a core-crosslinking of the micelles. 
The p(HPMA)-b-p(LMA-ran-HCMA) polymer was synthesized 
via RAFT polymerization of PFPMA with 4-cyano-4-((thiobenzoyl)
sulfanyl)pentaonic acid as CTA and AIBN as initiator. In a second 
step the p(PFPMA) homoblock was deployed as a macro-CTA for the 
polymerization of LMA and HCMA. After removing the dithiobenzoate 
end group the p(PFPMA)-b-p(LMA-ran-HCMA) precursorpolymer 
was transferred with 2-hydroxyaminopropanol via aminolysis into 
p(HPMA)-b-p(LMA-ran-HCMA).
Synthesis of PEG-NP: Core crosslinked nanoparticles containing 
covalently entrapped docetaxel (CPC634) were prepared and 
characterized as fully described in detail before.[21]
Synthesis of pSar-Brushes (pSar-NP): PSar brushes were prepared and 
characterized as fully described in detail before.[49] In addition, after 
the full Sar-NCA conversion, the secondary amine end groups of the 
pSar brushes were quenched with azido butyric acid pentafluorophenyl 
ester introducing terminal azide functionalities for subsequent selective 
conjugation of biologically active substrates.
Synthesis of Cyanin7 Functionalized pHPMA NPs: Poly(N-(2-hydroxypropyl) 
methacrylamide)-b-poly(lauryl methacrylate-ran-hymecromone methacrylate) 
block copolymers for cyanin7 functionalized pHPMA micelles were 
synthesized analogous to the unfunctionalized pHPMA NPs but by 
using an azide-functionalized CTA for RAFT polymerization.[64,65] After 
preparation and crosslinking of the micelles they were functionalized 
with cyanin7-DBCO from Lumiprobe. For the functionalization step a 
DMSO-water-solution (65:35, v:v) of Cyanin7-DBCO was added to a PBS 
solution of the crosslinked micelles in a molar ratio of 1 to 3 (dye to 
polymer) and the reaction solution was stirred (500 rpm) overnight at 35 °C. 
The reaction solution was then filtrated with Amikon Ultra Centrifugal 
Filters from Merck Millipore with a regenerated cellulose membrane 
and a molecular weight cut off of 30 kDa and washed with 20 mL Milli-Q 
water to remove free dye. Subsequently the solution was further purified 
via HPLC. Preparative size exclusion chromatography was performed via 
an Agilent 1100 System (Agilent, Germany). A volume of 100 µL of the 
NP solution was injected into the system running with PBS at a flow rate 
of 1 mL per min. A BioRad UNO Q1 column (BioRad, Munich, Germany) 
filled with Sephajzz S-500 (GE Healthcare) was used for separation. A 
multiwavelength detector (G1365A Agilent 1100 Series, Germany) was 
used for the detection of the absorption of Cyanin7-labeled NPs. An 
automated fraction collector collected the resulting purified NP solution.
Synthesis of Functionalized pSar-Brushes (Dye 800 CW and Antibody 
aDEC205)—Dye labeling: The dye 800CW-DBCO was conjugated to the 
pSar brushes via SPAAC. In a typical experiment, brushes were dissolved 
in PBS (β = 50 g L−1) and the dye was dissolved in DMSO (c = 5 × 10−3 m). 
As the reaction was quantitative, 1 equivalent of the desired amount 
of dyes per brush was added. After incubation (continuous agitation 
at 550  rpm) overnight at 20 °C under light exclusion, the reaction 
mixture was purified by Amicon Ultra Centrifugal Filter Devices to 
remove unbound dye and DMSO (15 mL, 50 kDa, 4000 × g, 10 times). 
The resulting solution was concentrated with Amicon Ultra Centrifugal 
Filter Devices (50  kDa, 4000 × g), filtered through sterile 0.22  µm 
Millex-GS filters and stored at −20 °C.
Synthesis of Functionalized pSar-Brushes (Dye 800 CW and Antibody 
aDEC205)—Synthesis of DBCO-Functionalized aDEC205 Antibodies: 
In a typical experiment, 2 eq. DBCO-PEG4-NHS-Ester (dissolved in 
DMSO, c  = 10  g L−1) were added to aDEC205. aDEC205 was used as 
received (dissolved in buffer, c(aDEC205) = 4,7 g L−1). After incubation 
(continuous agitation at 550  rpm) overnight at 20 °C, the reaction 
mixture was purified by Amicon Ultra Centrifugal Filter Devices (15 mL, 
10  kDa, 4000 × g, 10 times) to remove unbound DBCO-PEG4-NHS-
Ester, NHS and DMSO. Afterward preparative SEC was performed 
using a Sepharose 4 FF XK 16/70 column (flow 0.5 mL min−1) to remove 
aggregates. The resulting solution was concentrated with Amicon Ultra 
Centrifugal Filter Devices (10  kDa, 4000 × g), filtered through sterile 
0.22 µm Millex-GS filters and stored at −20 °C. Yield: 80–90 %.
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Synthesis of Functionalized pSar-Brushes (Dye 800 CW and Antibody 
aDEC205)—Synthesis of aDEC205 pSar Brushes: The amount of the 
DBCO-modified aDEC205 antibody that needs to be added depends 
on the number of DBCO per antibody (N_DBCO between 1–2). 
1/(0.34·N_DBCO) equivalents of the DBCO antibody (dissolved in PBS, 
c(aDEC205-DBCO) = 5–15 g L−1) were added to the pSar brush dissolved 
in PBS (c  = 1·10−5–1·10−6 m). The reaction mixture was incubated 
(continuous agitation at 550 rpm) overnight at 20 °C. To remove bridged 
brushes and unconjugated bioactive components, brush-conjugates 
were purified via preparative SEC using a Sepharose 4 FF XK 16/70 
column (flow 0.5  mL min−1). The fractions were concentrated using 
Amicon Ultra Centrifugal Filter Devices (50  kDa, 4000 × g), filtered 
through sterile 0.22 µm Millex-GS filters and stored at −20 °C.
In Vivo Experiments—Circulation Time of pSar Brushes in Mice: For 
determination of the circulation time BALB/c mice were anesthetized 
with isoflurane prior to injection of the 800CW functionalized pSar 
brushes (150  µL in PBS (c(Dye) = 1.5 × 10−5 m) intravenously and 
blood kinetics were determined by retrieval of blood at indicated time 
points. Briefly, retrieved blood samples (50  µL) were collected in a 
black 96-well plate and fluorescence intensities were determined with 
the IVIS Spectrum Imaging system (Perkin Elmer) using the filter set 
at 745 nm for excitation and at 800 nm for emission with an integration 
time of 3 s.
In Vivo Experiments—Circulation Time of pHPMA NPs in Mice—Animal 
Preparation: All mice were inhalation-anesthetized with 4.0% isoflurane 
in oxygen-enriched air in a mouse induction chamber and with 
2.0% isoflurane in oxygen-enriched air with a face mask during all 
experimental procedures. All animal experiments were approved by 
local and institutional ethical committees. 6–8 weeks old BALB/cAnNRj 
female mice (Janvier Labs, France) were used to have a syngeneic mouse 
model due to the fact that the 4T1 breast cancer cells were collected from 
identical individuals. Thus, the syngeneic BALB/c mouse model allows 
to study how cancer therapies perform in conjunction with a functional 
immune system and serve as a surrogate for human patients. The 
mice were kept in pathogen-free cages having their own ventilation and 
placed in rooms with controlled 12 h light/dark cycles. Mouse 4T1 breast 
cancer cells (American Type Culture Collection, Manassas, VA, USA) 
were cultured in RPMI medium (RPMI 1640; Gibco, Life Technologies 
GmbH, Germany), supplemented with 10% fetal bovine serum (FBS; 
Life Technologies GmbH, Germany) and 1% penicillin/streptomycin 
(10000 U mL−1 penicillin; 10  mg mL−1 streptomycin, Life Technologies 
GmbH, Germany), at 37 °C and 5% CO2 in a humid atmosphere. Tumors 
were induced by inoculating 2.5  ×  104 4T1 cells orthotopically into the 
right abdominal mammary gland of the mice. Tumors were allowed to 
grow for 10 days, until they reached a size of 5  mm in diameter. The 
weight and tumor size were controlled every day.
In Vivo Experiments—Circulation Time of pHPMA NPs in Mice—CT-FLT 
Imaging: For intravenous probe injection, a sterile catheter was placed 
into the lateral tail vein of the mouse. The catheter was prepared 
beforehand by connecting a 30 G cannula (B.Braun, Melsungen, 
Germany) to a polyethylene tube with an inner diameter of 0.28  mm 
and outer diameter of 0.61  mm, and a wall thickness of 0.165  mm 
(Hartenstein, Würzburg, Germany). At a tumor size of 5  mm all mice 
were i.v. injected with the cyanin7-labeled pHPMA nanoparticles 
(2  nmol; in 50  µL 0,9% NaCl sterile solution) for quantifying the 
biodistribution and blood circulation time (data on biodistribution is 
shown in Figure S15). The blood was taken from the tail vein at different 
time points to measure the blood half-life over 72 h. After the last CT-FLT 
scan, the animals were sacrificed, and organs were excised for ex vivo 
evaluation.
In Vivo Experiments—Circulation Time of PEG NPs in Mice: For 
determination of the circulation time BALB/c mice were anesthetized 
with isoflurane prior to intravenous injection of the PEG NPs 
(CPC634).[21] The dose of CPC634 was determined by the body weight of 
each mouse (30 mg kg−1). Blood kinetics were determined by retrieval of 
blood at indicated time points. Retrieved blood samples were collected 
and the concentration of total docetaxel (still covalently entrapped plus 
already released) was determined via LC-MS/MS as described in.[51]
In Vivo Experiments—Circulation Time of PEG NPs in Patients: The 
circulation time of PEG-NPs (CPC634) was obtained in the context of 
a dose escalation phase 1 study of CPC634. Patients with solid tumors 
with no treatment options were included. The dose of CPC634 was 
determined by the body surface area of each patient (60  mg m−2). 
CPC634 was administered i.v. as an 1 h infusion. Blood samples were 
taken at indicated time points and the concentration of total docetaxel 
(still covalently entrapped plus already released) was determined via 
LC-MS/MSas described in.[51]
Incubation with Human Blood Plasma: All nanoparticles (30 mg mL−1) 
were incubated with EDTA-stabilized, pure and undiluted plasma 1:1 
(v:v) at 37 °C for 1 h. The concentration of nanoparticles during plasma 
incubation was thus higher than during possible in vivo scenario, for 
which they were calculated to be 0.133 mg mL−1 the in the blood pool.[66] 
For a sufficient separation, the AF4 was limited to a maximal plasma 
concentration of 5 vol%. Therefore, after incubation the samples had to 
be diluted with PBS to a particle concentration of 1.5 g L−1 and a 5 vol% 
solution of plasma and immediately measured in AF4.
Thus, to enable an incubation of the nanoparticles with undiluted 
plasma, the initial particle concentration had to be high, since the 
mixture had to be diluted before the AF4 measurement.
Separation by AF4: The AF4 measurements were performed using an 
installation from the ConSenxuS GmbH. The setup was composed of a 
constaMETRICR 3200 main pump and a Spectra Series UV150 detector 
from Thermos Separation, a Dark V3 LS Detector from ConSenxuS 
GmbH, a Pharmacia P-3500 injection pump, a LV-F flow controller from 
HORIBA ATEC, a Waters In-Line Degasser-AF, and a separation channel 
with a 190 µm spacer and a reg. cellulose membrane with a molecular 
weight cutoff of 10 kDa, which was suitable for protein separation.[67] For 
the measurements with the PS NPs the UV absorption was detected at a 
wavelength of 280 nm, the UV absorption of all other NPs was detected 
at 220  nm. For all measurements except of those with polystyrene 
particles phosphate buffered saline (151.7 × 10−3 m) was used as solvent. 
For the polystyrene particles on the contrary—used as reference, shown 
in Figure S8 in the Supporting Information—a sodium chloride solution 
(4  × 10−3 m) was chosen and polyoxyethylen(20)-sorbitan-monolaurate 
(0.04 × 10−3 m) was added as detergent. Both solvents contained also 
sodium azide in a concentration of 0.2  × 10−3 m. The main flow was 
1 mL min−1 higher than the crossflow for each measurement. For each 
nanoparticle the crossflow is illustrated in the respective AF4 elugram. 
Every measurement was carried out at least three times from three 
independent incubation experiments. Nanoparticle fractions were 
collected from 13.3 to 16.6  min for PEG NPs, from 16.6 to 20  min 
for pSar NPs and from 15 to 18.3  min for pHPMA NPs. To increase 
the concentration of the collected fractions from the AF4 after the 
separation process, they were filtrated with Amikon Ultra Centrifugal 
Filters from Merck Millipore with a regenerated cellulose membrane 
and a molecular weight cut off of 3  kDa. Since even the smallest 
plasma proteins (such as β2 microglobulin) has a molecular weight of 
>10 kDa,[68] there should be no loss of proteins during the spin filtration.
Remark to the Rinse Peak: The rinsing was performed at the end 
of every measurement and was not part of the actual measurement. It 
consists of contributions from the general setup and it contains larger 
aggregates. So, it cannot be highly interpreted.
In these experiments, the rinse peak did not change during plasma 
incubation, so there was no sign of aggregation behavior (see also MALS 
detector in Figure S7 in the Supporting Information). On the other side, 
when aggregation between particles and proteins happens as shown in 
Figure S8 in the Supporting Information, it increases strongly.
But the particle and rinse peak of the characterized systems did 
not change (see also MALS detector in Figure S7 in the Supporting 
Information), so there was no sign of aggregation behavior and therefore 
no need to characterize the eluting fraction in the rinse time.
SDS PAGE: The SDS-PAGE experiments were performed following the 
general protocol of Laemmli.[69] The polyacrylamide gels were composed 
of a 12%-separation gel (with 8% stacking gel) and the electrophoresis 
was carried out for 45 min at 200 V with a Mini-PROTEAN Tetra Vertical 
electrophoresis-chamber from BIO-RAD. 7.5  µL of each sample was 
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incubated with 2.5  µL loading buffer (NuPAGE LDS Sample Buffer, 
Invitrogen) for 5 min at 95 °C. Novex Sharp Pre-Stained Protein Standard 
from INVITROGEN was loaded on each gel as a protein ladder for 
comparison. The proteins in the gels were visualized using a Coomassie 
Blue treatment and a silver staining.
DLS: For dynamic light scattering experiments the collected fractions 
from the AF4 were prepared in a dustfree flowbox. They were filtered with 
syringe filters from PALL Life Science with a diameter of 13  mm and a 
GHP membrane (0.2 µm pores) into dust free cylindrical scattering cells 
(Suprasil, 20 mm diameter). The measurements were performed with a 
Uniphase He/Ne Laser (632.8 nm, 22 mW), an ALV-SP125 Goniometer, an 
ALV/High QE APD-Avalanche photodiode, an ALV5000/E/PCI-correlator 
and a Lauda RC-6 thermostat unit. All angular dependent measurements 
were carried out in 20° steps between 30° and 150°. Data analysis was 
performed according to the procedure described by Rausch et al.[55,70]
Zetapotential: For zeta potential analysis, a Malvern Zetasizer NanoZS 
was used. Samples were prepared at 1  mg mL−1 in a sodium chloride 
(10  × 10−3 m) solution. Each sample was independently measured 
5 times and analyzed by its mean average and standard deviation.
Protein Digestion: Lyophilized protein corona proteins were digested 
according to the SP3 (“Single-Pot Solid-Phase-Enhanced Sample 
Preparation”) protocol.[59] After solubilization in SDS-Lysis buffer 
(1% SDS, 1× complete Protease Inhibitor Cocktail-EDTA, 50  × 10−3 m 
HEPES, pH 8,5), proteins were reduced by adding 5  µL of 200  × 10−3 m  
Dithiothreitol (DTT) per 100  µL lysate (45 °C, 30  min). Free cysteines 
were subsequently alkylated by adding 10 µL 100 × 10−3 m Iodoacetamide 
(IAA) per 100  µL lysate (Room temperature, 30  min, in the dark). 
Subsequently, remaining IAA was quenched by adding 10 µL 200 × 10−3 m  
DTT per 100  µL lysate. Magnetic carboxylate modified particles Beads 
(SpeedBeads, Sigma) were used for Protein Clean-up and Acetonitrile 
(ACN), in a final concentration of 70%, was added to the samples 
to induce the binding of the proteins to the beads by hydrophilic 
interactions (Room temperature, 18  min). By incubating the bead-
protein mixture on a magnetic stand for 2 min, the sample was bound to 
the magnet and the supernatant was removed, followed by two washing-
steps with 70% ethanol (EtOH), addition of 180 µL ACN, incubation for 
15 s and removal of the solvent. Finally, 5 µL digest buffer (50 × 10−3 m 
ammonium bicarbonate, 1:25 w/w trypsin:protein ratio) were added to 
the air-dried bead-protein mixtures and incubated over night at 37 °C. To 
purify peptides after digestion, ACN was added to a final concentration 
of 95%. After another washing step (s. Sielaff et  al., 2017 for detailed 
information) the beads were resuspended in 10 µL 2% DMSO (in water), 
put into an ultrasonic bath for 1 min and then shortly centrifuged. 10 µL 
of the resulting supernatant was mixed with 5 µL 100 fmol µL−1 Enolase 
digest (Waters, Eschborn, Germany) and acidified with 5 µL 1% formic 
acid (FA).
LC-MS Analysis: Liquid chromatography (LC) of tryptic peptides 
was performed on a NanoAQUITY UPLC system (Waters Corporation, 
Milford, MA) equipped with 75 × 10−6 m × 250 mm HSS-T3 C18 column 
(Waters Corporation). Mobile phase A was 0.1% (v/v) formic acid (FA) 
and 3% (v/v) dimethyl sulfoxide (DMSO) in water. Mobile phase B was 
0.1% (v/v) FA and 3% (v/v) DMSO in acetonitrile (ACN). Peptides were 
separated running a gradient from 5 to 60% (v/v) mobile phase B at a 
flow rate of 300 nL min−1 over 60 min. The column was heated to 55 °C. 
MS analysis of eluting peptides was performed by data-independent 
acquisition (DIA) in MSE. In brief, precursor ion information was 
collected in low-energy MS mode at a constant collision energy of 4 eV. 
Fragment ion information was obtained in the elevated energy scan 
applying drift-time specific collision energies. The spectral acquisition 
time in each mode was 0.6 s with a 0.05 s-interscan delay resulting in 
an overall cycle time of 1.3 s for the acquisition of one cycle of low and 
elevated energy data. [Glu1]-fibrinopeptide was used as lock mass at 
100 fmol µL−1 and sampled every 30 s into the mass spectrometer via 
the reference sprayer of the NanoLockSpray source. All samples were 
analyzed in three technical replicates.
Data Processing and Label-Free Quantification: MSE data processing 
and database search was performed using ProteinLynx Global Server 
(PLGS, ver. 3.0.2, Waters Corporation). The resulting proteins were 
searched against UniProt Human proteome database (UniProtKB 
release 2017_05, 20 201 entries) supplemented with a list of common 
contaminants. The database search was specified by trypsin as enzyme 
for digestion and peptides with up to two missed cleavages were 
included. Furthermore, Carbamidomethyl cysteine was set as fixed 
modification and oxidized methionine as variable modification. False 
discovery rate (FDR) assessment for peptide and protein identification 
was done using the target-decoy strategy by searching a reverse database 
and was set to 0.01 for database search in PLGS.
Retention time alignment, exact mass retention time (EMRT), as well 
as normalization and filtering was performed in ISOQuant ver.1.8.[71,72] 
By using TOP3 quantification,[73] absolute in-sample amounts of 
proteins were calculated. Statistical analysis was done in Perseus,[74] 
by performing two-tailed, paired -tests and subsequent Benjamini-
Hochberg correction.[75] Q-values < 0.05 were considered as significant.
Statement Regarding the Patient Data: Final clinical protocol, 
amendments, and informed consent documentation were approved 
by the Independent Ethics Committee (IEC) at the sites in Belgium and 
the Netherlands. Clinical studies were conducted in accordance with the 
ethical principles of the Declaration of Helsinki and are consistent with the 
International Council for Harmonisation (ICH) E6 Good Clinical Practice 
(GCP) guidelines and applicable national laws and regulatory requirements.
Patients provided their written informed consent to participate in the 
study after having been informed about the nature and purpose of the 
study, participation/termination conditions, and risks and benefits of 
treatment. Informed consent was obtained before the start of screening 
procedures from all patients.
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